UCSF Reports on Abiraterone Clinical Trial, PCF-Funding Leads Innovative Research Team
June 2, 2012 -- Lead author Charles J. Ryan, MD, at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco and his research team presented interim data results from a Phase III clinical trial on abiraterone acetate in metastatic, chemo resistant prostate cancer patients.
“We have identified that patients who have higher levels of androgen compared with those with lower levels have a better prognosis overall and a better prognosis when receiving abiraterone than patients with lower levels of androgens,” said Ryan. “Patients with low hormone levels seem to have a worse prognosis overall; however, they still benefitted significantly from receiving abiraterone as opposed to receiving placebo.”
Read more about Dr. Ryan and his colleagues work (listed below) on abiraterone, read a recap from the annual AACR meeting.
In addition to Dr. Ryan, six additional investigators on the team are supported by PCF, including Drs. Mathew Raymond Smith with Harvard Medical School, Johann Sebastian De Bono with The Institute for Cancer Research, Christopher Logothetis with MD Anderson Cancer Center, Eric Jay Small with University of California, San Francisco, Howard I. Scher with Memorial Sloan-Kettering Cancer Center and Dana E. Rathkopf with Memorial Sloan-Kettering Cancer Center.
Read the abstract from ASCO